Posts

Novo Nordisk halts two more IL-6 heart-drug trials for futility

Novo Nordisk has stopped two Phase 3 trials—HERMES and ATHENA—testing ziltivekimab, an experimental antibody that blocks the inflammatory signaling protein IL-6, in heart-failure patients. An independent data-monitoring committee concluded there was a low likelihood that either study would produce a successful result, a decision known as stopping for futility—not because of a newly reported safety problem. The move follows the July failure of the ZEUS trial, in which ziltivekimab lowered inflammatory biomarkers but did not reduce major cardiovascular events such as cardiovascular death, nonfatal heart attack, or nonfatal stroke. The company’s remaining major ziltivekimab study, ARTEMIS, is testing the drug in patients recovering from an acute heart attack and is continuing as planned, with results expected in the first half of 2027. The setbacks weaken Novo Nordisk’s effort to expand beyond its dominant diabetes and obesity medicines and raise broader questions about whether su...

Novartis drops after Avidity-acquired muscle-drug trial miss

Menarini licenses Gan & Lee’s biweekly GLP-1 drug for Europe

Ionis wins first-ever FDA approval for Alexander disease therapy

Recent BPSI trend: biopharma sentiment improving from pessimism to cautious optimism

Novartis may cut around 130 jobs in Switzerland while relocating biologics production

AbbVie’s T-cell engager shows survival benefit in Phase 3 multiple myeloma study

Pfizer Licenses Out Another Seagen ADC, Raising Fresh Questions About $43 Billion Deal

Novartis’ Rhapsido shows positive Phase 3 MS results, intensifying Roche competition

Pfizer licenses discontinued ADC to Medicus as Revolution Medicines updates lung-cancer data

China reportedly approves first AI-assisted innovative drug for marketing

Three takeaways from the latest White House drug-pricing event

GSK to license Hutchmed cancer drug for $110 million upfront